Abstract
ObjectiveTo identify patients at risk of mid-late term revision of hip replacement to inform targeted follow-up.DesignAnalysis of linked national data sets from primary and secondary care (Clinical Practice Research Datalink (CPRD-GOLD); National Joint Registry (NJR); English Hospital Episode Statistics (HES); Patient-Reported Outcome Measures (PROMs)).ParticipantsPrimary elective total hip replacement (THR) aged≥18.Event of interestRevision surgery≥5 years (mid-late term) after primary THR.Statistical methodsCox regression modelling to ascertain risk factors of mid-late term revision. HR and 95% CI assessed association of sociodemographic factors, comorbidities, medication, surgical variables and PROMs with mid-late term revision.ResultsNJR-HES-PROMs data were available from 2008 to 2011 on 142 275 THR; mean age 70.0 years and 61.9% female. CPRD GOLD-HES data covered 1995–2011 on 17 047 THR; mean age 68.4 years, 61.8% female. Patients had minimum 5 years postprimary surgery to end 2016. In NJR-HES-PROMS data, there were 3582 (2.5%) revisions, median time-to-revision after primary surgery 1.9 years (range 0.01–8.7), with 598 (0.4%) mid-late term revisions; in CPRD GOLD, 982 (5.8%) revisions, median time-to-revision 5.3 years (range 0–20), with 520 (3.1%) mid-late term revisions.Reduced risk of mid-late term revision was associated with older age at primary surgery (HR: 0.96; 95% CI: 0.95 to 0.96); better 6-month postoperative pain/function scores (HR: 0.35; 95% CI: 0.27 to 0.46); use of ceramic-on-ceramic (HR: 0.73; 95% CI: 0.56 to 0.95) or ceramic-on-polyethylene (HR: 0.76; 95% CI: 0.58 to 1.00) bearing surfaces.Increased risk of mid-late term revision was associated with the use of antidepressants (HR: 1.32; 95% CI: 1.09 to 1.59), glucocorticoid injections (HR: 1.33; 95% CI: 1.06 to 1.67) and femoral head size≥44 mm (HR: 2.56; 95% CI: 1.09 to 6.02)No association of gender, obesity or Index of Multiple Deprivation was observed.ConclusionThe risk of mid-late term THR is associated with age at primary surgery, 6-month postoperative pain and function and implant factors. Further work is needed to explore the associations with prescription medications observed in our data.
Funder
Health Services and Delivery Research Programme
Reference34 articles.
1. The use of patient-reported outcome measures to guide referral for hip and knee arthroplasty. Part 2: a cost-effectiveness analysis;Dakin;Bone Joint J,2020
2. National joint Registry . National joint Registry for England, Wales, Northern Ireland and the Isle of Man.17th annual report 2020, 2020. Available: https://reports.njrcentre.org.uk/ [Accessed 28 January 2021].
3. The lifetime risk of total hip and knee arthroplasty: results from the UK general practice research database
4. Future projections of total hip and knee arthroplasty in the UK: results from the UK Clinical Practice Research Datalink
5. British Hip Society, British Orthopaedic Association and Royal College of Surgeons of England . Commissioning guide: pain arising from the hip in adults, 2017. Available: https://www.boa.ac.uk/standards-guidance/commissioning-guides.html [Accessed 22 February 2021].
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献